



Revance to Release Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019

February 12, 2019

Conference Call Scheduled for Tuesday, February 26, 2019 at 4:30pm ET

NEWARK, Calif.--(BUSINESS WIRE)--Feb. 12, 2019-- Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the Company will release fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the close of market. Revance will host a corresponding conference call and a live webcast at 1:30pm PT/4:30pm ET on the same day to discuss the results and provide a business and pipeline update.

Individuals interested in listening to the conference call may do so by dialing (855) 453-3827 for domestic callers, or (484) 756-4301 for international callers and reference conference ID: 2298778; or from the webcast link in the investor relations section of the company's website at: www.revance.com.

A replay of the call will be available beginning February 26, 2019 at 4:30pm PT/7:30pm ET to February 27, 2019 at 4:30pm PT/7:30pm ET. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference conference ID: 2298778. The webcast will be available in the investor relations section on the company's website for 30 days following the completion of the call.

About Revance Therapeutics, Inc.

Revance Therapeutics is an emerging Silicon Valley biotechnology leader developing neuromodulators for the treatment of aesthetic and therapeutic conditions. Revance uses a unique proprietary peptide excipient technology to create novel, differentiated therapies. The company's lead compound, DaxibotulinumtoxinA for Injection (RT002), is in clinical development for a broad range of aesthetic and therapeutic indications, including glabellar lines, cervical dystonia, plantar fasciitis, upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. The company is advancing a robust pipeline of injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190212005114/en/>

Source: Revance Therapeutics, Inc.

INVESTORS

Revance Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
jherbert@revance.com

or

Burns McClellan, Inc.:
John Grimaldi, 212-213-0006
jgrimaldi@burnsmc.com

or

MEDIA

General Media:
TOGORUN:
Mariann Caprino, 917-242-1087
m.caprino@togorun.com

or

Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com